Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6TKP

Tankyrase 2 in complex with an inhibitor (OM-1900)

This is a non-PDB format compatible entry.
Summary for 6TKP
Entry DOI10.2210/pdb6tkp/pdb
DescriptorTankyrase-2, ~{N}-[3-[4-(2-chlorophenyl)-5-(5-ethoxypyridin-2-yl)-1,2,4-triazol-3-yl]cyclobutyl]-1,5-naphthyridine-4-carboxamide, ZINC ION, ... (4 entities in total)
Functional Keywordsinhibitor, complex, poly-adp-ribosylation, enzyme, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight55782.32
Authors
Sowa, S.T.,Lehtio, L. (deposition date: 2019-11-28, release date: 2020-07-08, Last modification date: 2024-01-24)
Primary citationWaaler, J.,Leenders, R.G.G.,Sowa, S.T.,Alam Brinch, S.,Lycke, M.,Nieczypor, P.,Aertssen, S.,Murthy, S.,Galera-Prat, A.,Damen, E.,Wegert, A.,Nazare, M.,Lehtio, L.,Krauss, S.
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
J.Med.Chem., 63:6834-6846, 2020
Cited by
PubMed Abstract: Tankyrases 1 and 2 are central biotargets in the WNT/β-catenin signaling and Hippo signaling pathways. We have previously developed tankyrase inhibitors bearing a 1,2,4-triazole moiety and binding predominantly to the adenosine binding site of the tankyrase catalytic domain. Here we describe a systematic structure-guided lead optimization approach of these tankyrase inhibitors. The central 1,2,4-triazole template and cyclobutyl linker of the lead compound were left unchanged, while side-group East, West, and South moieties were altered by introducing different building blocks defined as point mutations. The systematic study provided a novel series of compounds reaching picomolar IC inhibition in WNT/βcatenin signaling cellular reporter assay. The novel optimized lead resolves previous atropisomerism, solubility, and Caco-2 efflux liabilities. shows a favorable ADME profile, including improved Caco-2 permeability and oral bioavailability in mice, and exhibits antiproliferative efficacy in the colon cancer cell line COLO 320DM
PubMed: 32511917
DOI: 10.1021/acs.jmedchem.0c00208
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon